OncoMatch/Clinical Trials/NCT06221683
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Is NCT06221683 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for aml, childhood.
Treatment: Homoharringtonine · Cytarabine · Etoposide · Venetoclax · Mitoxantrone hydrochloride liposome · Recombinant Human Granulocyte Colony-Stimulating Factor · Idarubicin Hydrochloride · Sorafenib · Gilteritinib · Avapritinib — The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
Exception: hydroxyurea or cytarabine before diagnosis, cytarabine ≤ 5 days and total dose ≤ 500 mg/m2
Patients who have used hydroxyurea or cytarabine before diagnosis, but the dosage of cytarabine does not exceed 5 days, and the total dose does not exceed 500 mg/m2 (50 mg/m2, q12h × 5d)
Cannot have received: chemotherapy, radiotherapy, or immunotherapy
Exception: temporary only, not systemic therapy per protocol
Only temporary chemotherapy, radiotherapy, or immunotherapy, but not systematic treatment according to the treatment plan
Cannot have received: chemotherapy, radiotherapy, or immunotherapy
Exception: temporary only, not systemic therapy per protocol
Temporary chemotherapy, radiotherapy, or immunotherapy only, not systemic therapy per protocol
Lab requirements
Kidney function
creatinine clearance ≥50ml/min
Liver function
Tbil≤2×ULN, ALT/AST≤3×ULN
Cardiac function
NYHA grading<3; SaO2>92%
Liver function：Tbil≤2×ULN, ALT/AST≤3×ULN, creatinine clearance ≥50ml/min；Cardiac NYHA grading<3；SaO2>92%;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify